<code id='582AA66B64'></code><style id='582AA66B64'></style>
    • <acronym id='582AA66B64'></acronym>
      <center id='582AA66B64'><center id='582AA66B64'><tfoot id='582AA66B64'></tfoot></center><abbr id='582AA66B64'><dir id='582AA66B64'><tfoot id='582AA66B64'></tfoot><noframes id='582AA66B64'>

    • <optgroup id='582AA66B64'><strike id='582AA66B64'><sup id='582AA66B64'></sup></strike><code id='582AA66B64'></code></optgroup>
        1. <b id='582AA66B64'><label id='582AA66B64'><select id='582AA66B64'><dt id='582AA66B64'><span id='582AA66B64'></span></dt></select></label></b><u id='582AA66B64'></u>
          <i id='582AA66B64'><strike id='582AA66B64'><tt id='582AA66B64'><pre id='582AA66B64'></pre></tt></strike></i>

          knowledge

          knowledge

          author:comprehensive    Page View:32776
          the shape of a medical note connected by dots and lines — health tech coverage from STAT
          Adobe

          In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot use artificial intelligence or algorithms to deny medical services the government routinely covers.

          But in finalizing a rule to that effect, it also stepped into a thicket of questions from insurers about a technology that is especially difficult to pin down: What is AI? Can it be used at all to make decisions about the coverage of older patients? If so, how?

          advertisement

          This week, the federal agency that oversees Medicare sought to boil it all down into a simple directive: Put the circumstances of the individual patient first, and your algorithm second.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Wildfire smoke exposes gaps in outdoor worker protections
          Wildfire smoke exposes gaps in outdoor worker protections

          ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

          read more
          FDA grants conditional OK to Sarepta’s gene therapy for Duchenne
          FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

          KristofferTripplaar/SipaviaAPTheFoodandDrugAdministrationgrantedconditionalapprovalThursdaytothefirs

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Readout LOUD podcast: mifepristone case, GLP

          WhogetstosuetheFDA?Ispharmacaughtinatradewar?Andwhatdoes“AF”standfor?Wecoverallthatandmorethisweekon